Login to Your Account



Bench Press: BioWorld Looks at Translational Medicine


Monday, February 25, 2013

Inhibiting hepatitis C's nonstructural 5A, or NS5A, protein causes viral levels to drop by 99 percent within six hours of administration, and in one clinical trial, it led to sustained drops in viral levels in all treated patients – a stunning validation of the possibility of developing an all-oral hepatitis treatment regimen.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription